OPINION STATEMENT: Since the publication of the American @entity5 Society (ACS)/American Society for Colposcopy and Cervical Pathology (ASCCP)/American Society for Clinical Pathology (ASCP) clinical guidelines in 2012, the majority of practice organizations have reached a consensus on screening recommendations for a low-risk population. These guidelines were based on a thorough review of the evidence with reproducible methods to obtain high-quality, generalizable guidelines. Despite the strength of the evidence based recommendations comprising these guidelines, limitations in physician understanding and compliance remain with respect to reaching an unscreened population and defining and caring for @entity1 who are at "high risk." "High-risk" @entity1 are poorly characterized but should include @entity1 with a history of a prior abnormal screening, as data has shown a subsequent increased risk of @entity3146 ( @entity3146 ) or greater, even after treatment. These @entity1 warrant more intense screening than the general population-though there are no evidence-based guidelines for optimized screening protocols in this population. Emerging data in @entity5 screening this year includes the FDA approval of primary high-risk @entity1082 ) testing. While the data is promising, its role in clinical practice, impact on rates of colposcopy in a non-study population, and long-term outcomes are not fully understood, and ongoing research is needed. Challenges remain in this shifting environment on the optimal interval and modality for @entity5 screening to provide the greatest benefit in detection of @entity1613 while minimizing the harm of overtreatment. While rapid advancements in research provide improved knowledge on how to treat and prevent this disease, it is often difficult for providers across multiple specialties to remain abreast of these changes and to educate their @entity1 about the most current recommendations. Ultimately, provider and @entity1 education is critical both for improving primary prevention with HPV vaccination, as well as for the uptake of evidence-based screening and management guidelines aimed at detecting and treating @entity1613 .

Making Sense of Cervical XXXX Screening Guidelines and Recommendations.

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cervical cancer', 'Cancer'] @entity1082 :: ('10566', 'Species') :: ['human papillomavirus (HPV'] @entity1613 :: ('MESH:D011230', 'Disease') :: ['precancerous lesions', 'precancerous changes of the cervix'] @entity3146 :: ('MESH:D018290', 'Disease') :: ['CIN2', 'cervical intraepithelial neoplasia grade 2']
@entity5 :: (MESH:D009369,Disease) :: ['Cancer']
